Features | Partner Sites | Information | LinkXpress
Sign In

Thermo Fisher Scientific Showcases Expanded Offering for Clinical Laboratory

By Labmedica International staff writers
Posted on 29 Jul 2014
Image: Customers in clinical laboratories supporting hospitals, research institutions and government agencies are increasingly relying on ThermoFisher Scientific to achieve better diagnostics, improve patient care, and lower costs (Photo courtesy of Thermo Fisher Scientific).
Image: Customers in clinical laboratories supporting hospitals, research institutions and government agencies are increasingly relying on ThermoFisher Scientific to achieve better diagnostics, improve patient care, and lower costs (Photo courtesy of Thermo Fisher Scientific).
Thermo Fisher Scientific Inc. (Waltham, MA, USA) is introducing its Thermo Scientific and Life Technologies (Grand Island, NY, USA) products at the 2014 AACC Annual Meeting and Clinical Lab Expo. Thermo Fisher Scientific Inc. is highlighting its expanded portfolio of instruments, equipment, consumables, and software, for improving accuracy and efficiency in the clinical laboratory.

Marc N. Casper, president and CEO of Thermo Fisher Scientific comments “In the current healthcare environment, our customers in clinical laboratories supporting hospitals, research institutions, and government agencies are increasingly relying on better diagnostics to improve patient care and lower costs. We have the scale and depth of capabilities to help these customers drive accuracy and efficiency and ultimately improve the way healthcare is delivered.”

At AACC, Thermo Fisher will feature a range of products and services from its specialty diagnostics, analytical instrument, and genetic analysis portfolios including complete systems for aiding in the diagnosis of allergy and autoimmune diseases using ImmunoCAP and EliA blood tests such as the DRI Drugs of Abuse Assays, immunosuppressant assays, the CEDIA Cyclosporine Immunoassay, and the QMS Everolimus Immunoassay for therapeutic drug monitoring.

Next-generation sequencing platforms, including the Ion Torrent Personal Genome Machine and the Ion Chef automated sample preparation system for identifying genetic biomarkers of disease are also being shown. A new category of Thermo Scientific products, including high-performance liquid chromatography, mass spectrometry, and software designed and manufactured as US Food and Drug Association (FDA) Class 1 medical devices for use in laboratory-developed tests, and Thermo Scientific calibration and quality controls. In addition, the MAS LabLink Quality Assurance Program, a cloud-based application that offers an external perspective on daily QC and compares the data among peer laboratories will be revealed. Services including original equipment manufacturer (OEM) and custom services for development, manufacturing, and packaging of diagnostic products for third parties, as well as collaborative biomarker research and production services for industry and academia through the Thermo Fisher BRIMS center are introduced.

For a complete listing of products and services being showcased during AACC, please visit Thermo Fisher Scientific online (Please see Related Links below).

Related Links:

Thermo Fisher Scientific
Life Technologies



EUROIMMUN AG
KARL HECHT GMBH & CO KG
DIASYS DIAGNOSTIC SYSTEMS
WATERS CORPORATION

Channels

Genetic Tests

view channel
Image: The fully automated nCounter Analysis System (Photo courtesy of NanoString Technologies).

Blood Signature Analysis Helps Diagnose Parkinson’s Disease Earlier

The diagnosis of Parkinson's is usually not established until advanced neurodegeneration leads to clinically detectable symptoms involving the malfunction and death of vital nerve cells in the brain.... Read more

Pathology

view channel
Image: The cobas KRAS mutation real-time polymerase chain reaction test (Photo courtesy of Roche).

KRAS Mutation Test for Colorectal Cancer Diagnosis Approved

A real-time polymerase chain reaction test has been designed to identify the Kirsten rat sarcoma viral oncogene (KRAS) mutations in tumor samples from metastatic colorectal cancer (mCRC) patients and aid... Read more

Industry News

view channel

Main Factors Driving Revenue Growth in Clinical Chemistry Identified

According to a report by Kalorama Information (New York, NY, USA), overall growth in the clinical chemistry market will be modest, driven mainly by new tests and demographic changes, including an aging population and increasing number of people at risk of cardiovascular disease, such as those with hypertension, diabetes... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.